Lb Pharmaceuticals (LBRX) Research & Development (2024 - 2026)

Lb Pharmaceuticals' Research & Development history runs 3 years deep, the most recent figure standing at $14.6 million for Q1 2026.

• In Q1 2026, Research & Development rose 328.09% year-over-year to $14.6 million; the TTM figure through Mar 2026 stood at $29.0 million (changed N/A YoY), while the FY2025 annual figure was $16.7 million, down 67.28% from the prior year.
• Research & Development for Q1 2026 stood at $14.6 million, up from $8.5 million in the prior quarter.
• The five-year high for Research & Development was $14.6 million in Q1 2026, with the low at $376000.0 in Q4 2024.
• The 3-year median for Research & Development is $6.0 million (2025), against an average of $6.7 million.
• Peak annual rise in Research & Development reached 2156.12% in 2025, while the deepest fall reached 77.32% in 2025.
• Lb Pharmaceuticals' Research & Development stood at $376000.0 in 2024, then soared by 2156.12% to $8.5 million in 2025, then surged by 72.64% to $14.6 million in 2026.
• Business Quant data shows LBRX's Research & Development at $14.6 million in Q1 2026, $8.5 million in Q4 2025, and $2.4 million in Q3 2025.